{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:59Z","timestamp":1787840399962,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To compare the efficacy of subconjunctival administration of bevacizumab and different doses of sunitinib malate in reducing corneal neovascularization (CNV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In this experimental study, central corneal cauterization was created in the right eye of fifty male Sprague\u2013Dawley rats. On day 1 (1 week after cauterization), rats were randomly assigned into five treatment groups. Group control (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10) received subconjunctival injection of 0.02 ml of base saline solution. Group 1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10) received 0.02 ml of bevacizumab (25 mg\/ml). Group 2, 3, and 4 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10 for each group) were treated with 0.02 ml of sunitinib malate (10, 20, and 50 \u03bcg\/ml, respectively). On days 1, 7, and 14, digital photographs of the cornea were taken, and the area of CNV was measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      During the 2-week follow-up, CNV area in treatment groups was less than in control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). On day 7, corneal avascular area was highest in Group 3 at 63%. On day 14, the area of CNV in Groups 2 and 3 was less than in Group 1 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.031 and 0.011, respectively), but the difference between Groups 2 and 3 was not statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.552). The decreased CNV area on day 14 in Group 4 was significant in comparison to bevacizumab, but it was not significant on day 7 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.25 on day 7 and 0.002 on day 14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Subconjunctival sunitinib malate is more effective than bevacizumab in regressing CNV. This effect is more prominent on day 14.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1735-1995.200266","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T02:20:56Z","timestamp":1487211656000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats"],"prefix":"10.4103","volume":"22","author":[{"given":"Mohammad Nasser","family":"Hashemian","sequence":"first","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi Z.","family":"Mahrjerdi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Students Research Center, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mazloumi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona S","family":"Safizadeh","sequence":"additional","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadollah","family":"Shakiba","sequence":"additional","affiliation":[{"name":"Research Center of Immunologic Science, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouzeh","family":"Rahimi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Afarideh","sequence":"additional","affiliation":[{"name":"Students Research Center, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Ali","family":"Zare","sequence":"additional","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza Fallah","family":"Tafti","sequence":"additional","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram Bohrani","family":"Sepidan","sequence":"additional","affiliation":[{"name":"Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Abtahi","sequence":"additional","affiliation":[{"name":"Isfahan Eye Research Center, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed-Hossein","family":"Abtahi","sequence":"additional","affiliation":[{"name":"Isfahan Eye Research Center, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"R1-20250827","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R2-20250827","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00003226-199811000-00008","article-title":"Angiogenesis in corneal diseases: Histopathologic evaluation of 254 human corneal buttons with neovascularization","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"key":"R3-20250827","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00003226-200101000-00018","article-title":"Leukocytes in the early events of corneal neovascularization","volume":"20","author":"Gan","year":"2001","journal-title":"Cornea"},{"key":"R4-20250827","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"key":"R5-20250827","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","article-title":"Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization","volume":"247","author":"Han","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20250827","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2007.00800.x","article-title":"Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer","volume":"32","author":"Kr\u00e4mer","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R7-20250827","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"key":"R8-20250827","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R9-20250827","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-20250827","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-20250827","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"R12-20250827","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R13-20250827","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R14-20250827","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R15-20250827","first-page":"97","article-title":"The effects of topical everolimus and sunitinib on corneal neovascularization","volume":"35","author":"\u00c7akmak","year":"2016","journal-title":"Cutan Ocul Toxicol"},{"key":"R16-20250827","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R17-20250827","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2006.22.213","article-title":"A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo","volume":"22","author":"Takahashi","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"key":"R18-20250827","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":"Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (Anti-VEGF and Anti-PDGF) in an animal model","volume":"150","author":"P\u00e9rez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R19-20250827","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/ICO.0b013e3182801645","article-title":"Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model","volume":"32","author":"Ko","year":"2013","journal-title":"Cornea"},{"key":"R20-20250827","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-20250827","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R22-20250827","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: From rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"R23-20250827","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000322061","article-title":"Prevention of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats","volume":"46","author":"Hashemian","year":"2011","journal-title":"Ophthalmic Res"},{"key":"R24-20250827","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R25-20250827","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/02713683.2011.635916","article-title":"In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate","volume":"37","author":"Dib","year":"2012","journal-title":"Curr Eye Res"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01222967-201722000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:05Z","timestamp":1787836925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01222967-201722000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/1735-1995.200266","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2015-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}